Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

被引：0
|
作者：
Kilickap, S. [1 ]
Sezer, A. [2 ]
Ozguroglu, M. [3 ]
Gumus, M. [4 ]
Bondarenko, I. [5 ]
Gogishvili, M. [6 ]
Nechaeva, M. [7 ]
Schenker, M. [8 ]
Cicin, I. [1 ]
Fuang, H. G. [9 ]
Kulyaba, Y. [10 ]
Zyuhal, K. [11 ]
Scheusan, R. I. [12 ]
Baramidze, A. [13 ]
Garassino, M. C. [14 ]
Li, Y. [15 ]
Jia, X. [15 ]
Kaul, M. [15 ]
Perez, J. [15 ]
Seebach, F. [15 ]
Lowy, I. [15 ]
Pouliot, J. F. [15 ]
Kim, E. [15 ]
Rietschel, P. [15 ]
Magnan, H. [15 ]
机构：
[1] Istinye Univ, Fac Med, Istanbul, Turkiye
[2] Baskent Univ, Adana, Turkiye
[3] Istanbul Univ Cerrahpasa, Istanbul, Turkiye
[4] Istanbul Medeniyet Univ, Istanbul, Turkiye
[5] Dnipropetrovsk Med Acad, Dnipro, Ukraine
[6] Univ Clin, High Technol Med Ctr, Tbilisi, Georgia
[7] Div Arkhangelsk Clin Oncol Ctr, Arkhangelsk, Russia
[8] Centrul Oncol Sf Nectarie SRL, Craiova, Romania
[9] Univ Malaya, Kuala Lumpur, Malaysia
[10] Prognosis Optima LLC, Kyiv, Ukraine
[11] Multiprofile Hosp Active Treatment, Dobrich, Bulgaria
[12] Oncocenter Oncol Clin, Timisoara, Romania
[13] Todua Clin, Tbilisi, Georgia
[14] Univ Chicago, Knapp Ctr Biomed Discovery, Chicago, IL USA
[15] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA11.06
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [41] Flexibility in chemotherapy regimens in first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with cemiplimab in combination with chemotherapy: analysis from EMPOWER-Lung 3
    Rosen, Jan-Paul
    Makharadze, Tamta
    Gogishvili, Miranda
    Melkadze, Tamar
    Baramidze, Ana
    Zhu, Cong
    Mcintyre, Debra Ag
    Venkateshan, Satish
    Kim, Eric
    Magnan, Heather
    Pouliot, Jean -Francois
    LUNG CANCER, 2025, 200
  • [42] Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line
    Zhao, Yue
    Mao, Yousheng
    He, Jie
    Gao, Shugeng
    Zhang, Zhirong
    Ding, Ningning
    Xue, Qi
    Gao, Yushun
    Wang, Dali
    Zhao, Jun
    Tan, Fengwei
    Yuan, Ligong
    Li, Feng
    Wang, Shuaibo
    Yang, Lin
    CLINICAL LUNG CANCER, 2021, 22 (02) : E201 - E210
  • [43] BUDGET IMPACT ANALYSIS OF CEMIPLIMAB FOR FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1)≥ 50% IN ITALY
    Rumi, F.
    Xoxi, L.
    Cicchetti, A.
    VALUE IN HEALTH, 2022, 25 (12) : S147 - S147
  • [44] The Safety of First-line and Subsequent Monotherapy of PD-1/PD-L1 Inhibitors in NSCLC: A Meta Analysis
    Yang, Y.
    Xie, Z.
    Pang, P.
    Wang, N.
    Liang, H.
    Zhao, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1048 - S1049
  • [45] A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
    Awad, M. M.
    Hao, Y.
    Li, S.
    Kaul, M.
    Seebach, F.
    Goncalves, P.
    Brueck, P.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2023, 34
  • [46] Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC
    Xu, Yingqi
    Zhang, Yidan
    Qiang, Huiping
    Zhong, Hua
    Xu, Jianlin
    Zhong, Runbo
    LUNG CANCER, 2024, 194
  • [47] Long-term real- world outcomes of first-line (1L) pembrolizumab (pembro) monotherapy in PD-L1 ≥50% metastatic NSCLC.
    Velcheti, Vamsidhar
    Hu, Xiaohan
    Piperdi, Bilal
    Yang, Lingfeng
    Burke, Thomas A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial (vol 24, pg 989, 2023)
    Ozguroghu, M.
    Kilickap, S.
    Sezer, A.
    LANCET ONCOLOGY, 2023, 24 (10): : e405 - e405
  • [49] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [50] Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC)
    Masini, S.
    Garrido, A.
    Alvarez, R.
    Antonanzas, M.
    Navarro, F.
    Traseira, C.
    Cabezon, L.
    Garcia, C.
    Falagan, S.
    Rocha, P.
    Mosquera, J.
    Azkarate, A.
    Garcia-Lorenzo, E.
    Martin-Soberon, M. C.
    Sequero, S.
    Sereno, M.
    Lage, Y.
    Peressini, M.
    Cortijo, S.
    Bote, H.
    Torres-Jimenez, J.
    Zurera, M.
    Paz-Ares, L.
    Zugazagoitia, J.
    Baena, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S405 - S405
12345